Novo Nordisk has ended a legal dispute with telehealth company Hims & Hers and entered into a partnership with it to sell original semaglutide-containing drugs such as Ozempic and Wegovy[2]. Novo Nordisk initially sued Hims & Hers for patent infringement in February 2026 because the company was offering cheaper, unapproved copies of the weight loss drug for $49 in the first month, which was $100 less than Novo Nordisk's price[1]. Hims & Hers subsequently stopped selling these copies and announced that they would continue to offer original products[1][4]. The partnership between the two companies, which was announced at the end of April 2026, was intended to provide Hims & Hers with advantageous access to original medicines[4]. However, Novo Nordisk later terminated the cooperation due to the suspicion that Hims & Hers continued to offer modified versions of the drugs even after the signing of the agreement[4]. The active substance semaglutide remains protected by US patents until 2031 to 2032[1][6].